OBJECTIVE: To assess the characteristics of combination antiretroviral therapy (cART) administered concomitantly with chemotherapy and to establish prognostic determinants of patients with AIDS-related non-Hodgkin's lymphoma. METHODS: The study included 91 patients with AIDS-related non-Hodgkin's lymphoma from the Swiss HIV Cohort Study enrolled between January 1997 and October 2003, excluding lymphomas of the brain. We extracted AIDS-related non-Hodgkin's lymphoma- and HIV-specific variables at the time of lymphoma diagnosis as well as treatment changes over time from charts and from the Swiss HIV Cohort Study database. Cox regression analyses were performed to study predictors of overall and progression-free survival. RESULTS: During a median follow up of 1.6 years, 57 patients died or progressed. Thirty-five patients stopped chemotherapy prematurely (before the sixth cycle) usually due to disease progression; these patients had a shorter median survival than those who completed six or more cycles (14 versus 28 months). Interruptions of cART decreased from 35% before chemotherapy to 5% during chemotherapy. Factors associated with overall survival were CD4+ T-cell count (<100 cells/microl) (hazard ratio [HR] 2.95 [95% confidence interval (CI) 1.53-5.67], hepatitis C seropositivity (HR 2.39 [95% CI 1.01-5.67]), the international prognostic index score (HR 1.98-3.62 across categories) and Burkitt histological subtypes (HR 2.56 [95% CI 1.13-5.78]). CONCLUSIONS: Interruptions of cART were usually not induced by chemotherapy. The effect of cART interruptions on AIDS-related non-Hodgkin's lymphoma prognosis remains unclear, however, hepatitis C seropositivity emerged-as a predictor of death beyond the well-known international prognostic index score and CD4+ T-cell count.
OBJECTIVE: To assess the characteristics of combination antiretroviral therapy (cART) administered concomitantly with chemotherapy and to establish prognostic determinants of patients with AIDS-related non-Hodgkin's lymphoma. METHODS: The study included 91 patients with AIDS-related non-Hodgkin's lymphoma from the Swiss HIV Cohort Study enrolled between January 1997 and October 2003, excluding lymphomas of the brain. We extracted AIDS-related non-Hodgkin's lymphoma- and HIV-specific variables at the time of lymphoma diagnosis as well as treatment changes over time from charts and from the Swiss HIV Cohort Study database. Cox regression analyses were performed to study predictors of overall and progression-free survival. RESULTS: During a median follow up of 1.6 years, 57 patients died or progressed. Thirty-five patients stopped chemotherapy prematurely (before the sixth cycle) usually due to disease progression; these patients had a shorter median survival than those who completed six or more cycles (14 versus 28 months). Interruptions of cART decreased from 35% before chemotherapy to 5% during chemotherapy. Factors associated with overall survival were CD4+ T-cell count (<100 cells/microl) (hazard ratio [HR] 2.95 [95% confidence interval (CI) 1.53-5.67], hepatitis C seropositivity (HR 2.39 [95% CI 1.01-5.67]), the international prognostic index score (HR 1.98-3.62 across categories) and Burkitt histological subtypes (HR 2.56 [95% CI 1.13-5.78]). CONCLUSIONS: Interruptions of cART were usually not induced by chemotherapy. The effect of cART interruptions on AIDS-related non-Hodgkin's lymphoma prognosis remains unclear, however, hepatitis C seropositivity emerged-as a predictor of death beyond the well-known international prognostic index score and CD4+ T-cell count.
Authors: Chun Chao; Lanfang Xu; Donald Abrams; Wendy Leyden; Michael Horberg; William Towner; Daniel Klein; Beth Tang; Michael Silverberg Journal: AIDS Date: 2010-07-17 Impact factor: 4.177
Authors: Stefan K Barta; Xiaonan Xue; Dan Wang; Jeannette Y Lee; Lawrence D Kaplan; Josep-Maria Ribera; Albert Oriol; Michele Spina; Umberto Tirelli; Francois Boue; Wyndham H Wilson; Christoph Wyen; Kieron Dunleavy; Ariela Noy; Joseph A Sparano Journal: Haematologica Date: 2014-08-22 Impact factor: 9.941
Authors: A Antinori; A Ammassari; C Torti; P Marconi; M Andreoni; G Angarano; S Bonora; A Castagna; R Cauda; M Clerici; A d'Arminio Monforte; A De Luca; G Di Perri; M Galli; E Girardi; A Gori; A Lazzarin; S Lo Caputo; F Mazzotta; F Montella; C Mussini; C F Perno; M Puoti; G Rizzardini; S Rusconi; V Vullo; G Carosi Journal: Infection Date: 2009-05-28 Impact factor: 3.553
Authors: Julia Bohlius; Kurt Schmidlin; Dominique Costagliola; Gerd Fätkenheuer; Margaret May; Anna Maria Caro-Murillo; Amanda Mocroft; Fabrice Bonnet; Gary Clifford; Anastasia Karafoulidou; Jose M Miro; Jens Lundgren; Genevieve Chene; Matthias Egger Journal: Antivir Ther Date: 2009
Authors: Sunil Suhas Solomon; Aylur K Ganesh; Shruti H Mehta; Tokugha Yepthomi; Kavitha Balaji; Santhanam Anand; Joel E Gallant; Suniti Solomon Journal: Indian J Med Res Date: 2013-06 Impact factor: 2.375
Authors: Maudy C P Manyau; Tinashe Mudzviti; Simbarashe Rusakaniko; Elson T Mberi; Charles C Maponga; Gene D Morse Journal: PLoS One Date: 2020-09-17 Impact factor: 3.240
Authors: Luis Ernesto Cuellar; Andrea Anampa-Guzmán; Alexis Manuel Holguín; Juan Velarde; Diana Portillo-Alvarez; Marco Antonio Zuñiga-Ninaquispe; Esther Rosa Luna-Reyes; Jule Vásquez; Joanne Marie Jeter; Karen Marie Winkfield Journal: Infect Agent Cancer Date: 2018-07-31 Impact factor: 2.965